Latest Breaking News On - Abbvie biotechnology ltd - Page 12 : comparemela.com

Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Company Announcement TEPKINLY® is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma .

United statesNew jerseyComunidad autonoma de catalunaGenmab duobodyInstitut catalMarisol peronAndrew carlsenAnna suredaEuropean unionGlobal communications corporate affairsEuropean medicines agencyAdministration of tepkinlyEuropean commissionCompany announcementExchange commissionDevelopment of novel anti

Organon Reports Results for the Second Quarter Ended June 30, 2023

Organon Reports Results for the Second Quarter Ended June 30, 2023
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesJersey cityAsia pacificCozaar hyzaarKevin aliCelestone soluspanCelestone chronodoseMarvelon mercilonAbbvie biotechnology ltdOrganon coWomen healthMerck co incExchange commissionOther women healthEstablished brands

Genmab Announces Financial Results for the First Half of 2023

Genmab Announces Financial Results for the First Half of 2023
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesAndrew carlsenMarisol peronSeagen incJanssen biotech incGlobal communications corporate affairsCompany announcement noAbbvie incAbbvie biotechnology ltdDrug administrationExchange commissionAnnounces financial resultsFirst halfFirst six months ended juneChief executive officerPerformance first half

Genmab A/S: Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

Genmab A/S: Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesNew jerseyFrance generalDavid freundelCatherine thieblemontGenmab duobodyAndrew carlsenCommittee for medicinal products human useGenmab us incEuropean commissionParis universityAbbvie biotechnology ltdExchange commissionMacrophage propertiesj immunolDevelopment of novel antiProduct communications

Genmab Announces AbbVie Receives Positive CHMP Opinion for

Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary efficacy and.

United statesFrance generalNew jerseyCatherine thieblemontDavid freundelKalvebod bryggeAndrew carlsenGenmab duobodyMacrophage propertiesj immunolAbbvie biotechnology ltdUs incDevelopment of novel antiCompany announcementParis universityEuropean commissionExchange commission